Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
Phase 3 Completed
482 enrolled
Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin
Phase 3 Completed
167 enrolled
Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy
Completed
40 enrolled
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
Phase 2 Completed
57 enrolled 9 charts
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
Phase 3 Completed
432 enrolled 7 charts
Cognitive Effects of Interferon in Patients With Melanoma
Completed
36 enrolled
Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis
Phase 3 Completed
3,000 enrolled
Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma
Phase 3 Completed
1,000 enrolled
Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma
Phase 2 Completed
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
Phase 2 Completed
60 enrolled
Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma
Phase 2 Completed
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
Phase 2 Completed
40 enrolled
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma
Phase 1 Completed
30 enrolled
Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)
Phase 4 Completed
49 enrolled
Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase 2 Completed
90 enrolled
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
Phase 3 Completed
140 enrolled
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
Phase 2 Completed
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer
Phase 2 Completed
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma
Phase 2 Completed
40 enrolled
Biological Therapy in Treating Patients With Metastatic Cancer
Phase 2 Completed
30 enrolled
Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
Phase 2 Completed
488 enrolled 12 charts